IFW

MAY 2 4 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Confirmation No:

DEL SOLDATO et al.

Group Art Unit:

Application Serial No.: 10/577,912

Examiner:

Filed: May 1, 2006

Attorney Docket No.: 026220-00082

For: Nitrooxyderivatives of Carvedilol and Other Beta Blockers as Antihypertensive

Drugs

May 24, 2006

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08a. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Action	This Information Disclosure Statement is being filed (a) within three as of the U.S. filing date, OR (b) before the mailing date of a first Office on the merits in the present application, OR (c) accompanies a lest for Continued Examination. No certification or fee is required.			
2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.				
	a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).			

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons an	e required to respond to a collection	on of friormation unless it contains a valid OWB control number.	
	Substitute for form 1449A/PTO	Complete if Known		
,	OTH INFORMATION DISCLOSURE	Application Number	10/577,912	
•	9 ANTORIMATION DISCLOSURE	Filing Date	May 1, 2006	
	STATEMENT BY APPLICANT	First Named Inventor	DEL SOLDATO	
	MAY 2 4 7006 Form PTO/SB/08a	Art Unit		
	(بيز ٥٥٥٠)	Examiner Name		
,	Sheet of 1	Attorney Docket Number	026220-00082	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,801,596		01/31/1989	Simon et al.	
		US-5,502,237		03/26/1996	Prat Quin et al.	
		US-5,639,904		07/08/1997	Prat Quinones et al.	
		US-6,242,432		05/05/2001	Del Soldato	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	1	US-				
		US-				
		US-				
		US-				
		US-				
	†	US-				
		US-				
		US-				
	 	US-				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Country Code ³	Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
								<u> </u>
					····			<u> </u>
								
	 							
	1							
	1							

Examiner	Date	
Signature	Considered	
Oigi idiai o		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2). c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
	or Not hereb Attach under overp	This Information Disclosure Statement is being filed more than three as after the U.S. filing date and after the mailing date of a Final Rejection tice of Allowance, but before payment of the Issue Fee. Applicant(s) by petition(s) that the Information Disclosure Statement be considered. The discource considered is our check in the amount of \$180.00 in payment of the petition fee 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any ayment to Deposit Account No. 01-2300 as needed to ensure deration of the disclosed information.
		a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filling of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
	enclo	The relevance of the non-English language references are discussed present specification. A copy of the U.S. Patent reference is not sed in view of the recent changes in the U.S. Patent rules effective per 21, 2004.
		Respectfully submitted,
		Richard J Berman Registration No.: 39,107 Direct Telephone No.: 202-857-6232
Custo	omer N	o.: 004372
4050	0	Alleria Arranica ALVAI

1050 Connecticut Avenue, N.W. Washington, D.C. 20036-5339 Telephone No.: 202-857-6000 Facsimile No.: 202-857-6395

RJB/pdc